GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Newbury Pharmaceuticals AB (OSTO:NEWBRY) » Definitions » Beneish M-Score

Newbury Pharmaceuticals AB (OSTO:NEWBRY) Beneish M-Score : -0.76 (As of Apr. 11, 2025)


View and export this data going back to 2022. Start your Free Trial

What is Newbury Pharmaceuticals AB Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -0.76 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Newbury Pharmaceuticals AB's Beneish M-Score or its related term are showing as below:

OSTO:NEWBRY' s Beneish M-Score Range Over the Past 10 Years
Min: -2.79   Med: -0.59   Max: 3.2
Current: -0.76

During the past 4 years, the highest Beneish M-Score of Newbury Pharmaceuticals AB was 3.20. The lowest was -2.79. And the median was -0.59.


Newbury Pharmaceuticals AB Beneish M-Score Historical Data

The historical data trend for Newbury Pharmaceuticals AB's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Newbury Pharmaceuticals AB Beneish M-Score Chart

Newbury Pharmaceuticals AB Annual Data
Trend Aug21 Aug22 Aug23 Aug24
Beneish M-Score
- - 3.08 -0.76

Newbury Pharmaceuticals AB Quarterly Data
Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.70 -0.54 -2.10 -0.76 -2.79

Competitive Comparison of Newbury Pharmaceuticals AB's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Newbury Pharmaceuticals AB's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Newbury Pharmaceuticals AB's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Newbury Pharmaceuticals AB's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Newbury Pharmaceuticals AB's Beneish M-Score falls into.


;
;

Newbury Pharmaceuticals AB Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Newbury Pharmaceuticals AB for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.3975+0.528 * 0.8834+0.404 * 0.8238+0.892 * 3.5875+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1+4.679 * 0.09136-0.327 * 2.0077
=-0.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Aug24) TTM:Last Year (Aug23) TTM:
Total Receivables was kr23.68 Mil.
Revenue was kr36.83 Mil.
Gross Profit was kr16.03 Mil.
Total Current Assets was kr43.97 Mil.
Total Assets was kr90.87 Mil.
Property, Plant and Equipment(Net PPE) was kr0.00 Mil.
Depreciation, Depletion and Amortization(DDA) was kr1.74 Mil.
Selling, General, & Admin. Expense(SGA) was kr0.00 Mil.
Total Current Liabilities was kr29.45 Mil.
Long-Term Debt & Capital Lease Obligation was kr0.00 Mil.
Net Income was kr-15.41 Mil.
Gross Profit was kr0.00 Mil.
Cash Flow from Operations was kr-23.71 Mil.
Total Receivables was kr16.60 Mil.
Revenue was kr10.27 Mil.
Gross Profit was kr3.95 Mil.
Total Current Assets was kr27.24 Mil.
Total Assets was kr72.92 Mil.
Property, Plant and Equipment(Net PPE) was kr0.00 Mil.
Depreciation, Depletion and Amortization(DDA) was kr1.26 Mil.
Selling, General, & Admin. Expense(SGA) was kr0.00 Mil.
Total Current Liabilities was kr11.77 Mil.
Long-Term Debt & Capital Lease Obligation was kr0.00 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(23.675 / 36.829) / (16.603 / 10.266)
=0.642836 / 1.61728
=0.3975

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(3.948 / 10.266) / (16.033 / 36.829)
=0.38457 / 0.435336
=0.8834

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (43.973 + 0) / 90.871) / (1 - (27.236 + 0) / 72.918)
=0.516094 / 0.626485
=0.8238

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=36.829 / 10.266
=3.5875

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.255 / (1.255 + 0)) / (1.738 / (1.738 + 0))
=1 / 1
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0 / 36.829) / (0 / 10.266)
=0 / 0
=1

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 29.446) / 90.871) / ((0 + 11.769) / 72.918)
=0.324042 / 0.1614
=2.0077

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-15.405 - 0 - -23.707) / 90.871
=0.09136

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Newbury Pharmaceuticals AB has a M-score of -0.76 signals that the company is likely to be a manipulator.


Newbury Pharmaceuticals AB Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Newbury Pharmaceuticals AB's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Newbury Pharmaceuticals AB Business Description

Traded in Other Exchanges
N/A
Address
Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Newbury Pharmaceuticals AB is a hybrid pharmaceutical company for specialty prescription drugs, innovation and brands with focus on the Scandinavian markets.

Newbury Pharmaceuticals AB Headlines

No Headlines